CT Perfusion Parameters for Advanced HCC Treated by Systemic Immunotherapy

Valérie LAURENT

Status: Completed

Conditions: Advanced HCC Treated by Systemic Immunotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT05580809

2022PI117

Details and patient eligibility

About

The purpose of this study is to compare CT perfusion parameters to RECIST 1.1 and mRECIST assessment for advanced HCC treated by systemic immunotherapy, and to evaluate perfusion parameters as predictive factors of response on baseline and on early follow-up

Enrollment: 9 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients > 18 years old
• Proved HCC
• Advanced HCC, defined as Barcelona Clinic Liver Classifications (BCLC) stage B non eligible for loco-regional therapy and stage C
• No prior systemic therapy
• Measurable disease per Response Evaluation Criteria for Solid Tumour (RECIST) v1.1
• Child-Pugh Score = A
• Eastern Cooperative Oncology Group (ECOG) Performance Status < 2

Exclusion criteria

• Absence of CT perfusion before treatment initiation more than a two-month delay between treatment initiation and first post-treatment CT perfusion
• Uninterpretable CT perfusion
• Definitive contraindication to CT perfusion (allergy or advanced renal disease)